1. Rhee EJ, Kim JH, Moon SJ, Lee WY. Encountering COVID-19 as endocrinologists. Endocrinol Metab (Seoul) 2020;35:197-205.
[CROSSREF] [PUBMED] [PMC]
2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-16.
[CROSSREF] [PUBMED]
3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603-15.
[CROSSREF] [PUBMED]
5. Katznelson L, Gadelha M. Glucocorticoid use in patients with adrenal insufficiency following administration of the COVID-19 vaccine: a pituitary society statement. Pituitary 2021;24:143-5.
[CROSSREF] [PUBMED] [PMC]
6. Puig-Domingo M, Marazuela M, Yildiz BO, Giustina A. COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology. Endocrine 2021;72:301-16.
[CROSSREF] [PUBMED] [PMC]
7. Serban AL, Ferrante E, Carosi G, Indirli R, Arosio M, Mantovani G. COVID-19 in Cushing disease: experience of a single tertiary centre in Lombardy. J Endocrinol Invest 2021;44:1335-6.
[CROSSREF] [PUBMED]
8. Adir Y, Humbert M, Saliba W. COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: nationwide real-world evidence. J Allergy Clin Immunol 2021;148:361-7.
[CROSSREF] [PUBMED] [PMC]
9. Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 2020;159:481-91.
[CROSSREF] [PUBMED]
10. Arlt W, Baldeweg SE, Pearce SHS, Simpson HL. Endocrinology in the time of COVID-19: management of adrenal insufficiency. Eur J Endocrinol 2020;183:G25-32.
[CROSSREF] [PUBMED] [PMC]
11. Stewart PM, Biller BM, Marelli C, Gunnarsson C, Ryan MP, Johannsson G. Exploring inpatient hospitalizations and morbidity in patients with adrenal insufficiency. J Clin Endocrinol Metab 2016;101:4843-50.
[CROSSREF] [PUBMED]
12. Carosi G, Morelli V, Del Sindaco G, Serban AL, Cremaschi A, Frigerio S, et al. Adrenal insufficiency at the time of COVID-19: a retrospective study in patients referring to a tertiary center. J Clin Endocrinol Metab 2021;106:e1354-61.
[CROSSREF]
13. Inoue S, Shibata Y, Takabatake N, Igarashi A, Abe S, Kubota I. Influence of corticosteroid therapy on the serum antibody response to influenza vaccine in elderly patients with chronic pulmonary diseases. EXCLI J 2013;12:760-5.
[PUBMED] [PMC]
14. Chung SM, Lee YY, Ha E, Yoon JS, Won KC, Lee HW, et al. The risk of diabetes on clinical outcomes in patients with coronavirus disease 2019: a retrospective cohort study. Diabetes Metab J 2020;44:405-13.
[CROSSREF] [PUBMED] [PMC]
15. Gregory JM, Slaughter JC, Duffus SH, Smith TJ, LeStourgeon LM, Jaser SS, et al. COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic’s impact in type 1 and type 2 diabetes. Diabetes Care 2021;44:526-32.
[CROSSREF] [PUBMED]
16. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 2020;14:395-403.
[CROSSREF] [PUBMED] [PMC]
17. Kim MK, Jeon JH, Kim SW, Moon JS, Cho NH, Han E, et al. The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea. Diabetes Metab J 2020;44:602-13.
[CROSSREF] [PUBMED] [PMC]
18. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 2021;17:11-30.
[CROSSREF] [PUBMED]
19. Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol 2020;8:813-22.
[CROSSREF] [PUBMED] [PMC]
20. Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020;63:1500-15.
[CROSSREF] [PUBMED] [PMC]
21. Moon SJ, Rhee EJ, Jung JH, Han KD, Kim SR, Lee WY, et al. Independent impact of diabetes on the severity of coronavirus disease 2019 in 5,307 patients in South Korea: a nationwide cohort study. Diabetes Metab J 2020;44:737-46.
[CROSSREF] [PUBMED] [PMC]
22. Pal R, Bhadada SK, Misra A. COVID-19 vaccination in patients with diabetes mellitus: current concepts, uncertainties and challenges. Diabetes Metab Syndr 2021;15:505-8.
[CROSSREF] [PUBMED] [PMC]
24. Dooling K, Marin M, Wallace M, McClung N, Chamberland M, Lee GM, et al. The advisory committee on immunization practices’ updated interim recommendation for allocation of COVID-19 vaccine: United States, December 2020. MMWR 2021;69:1657-60.
[CROSSREF] [PUBMED] [PMC]
25. Central Disaster Management Headquarters. Who first gets the COVID-19 vaccination? [Internet] Cheongju: Korea Disease Control and Prevention Agency; 2021 [cited 2021 Aug 9]. Available from:
https://ncv.kdca.go.kr/menu.es?mid=a10117010000
.
27. European Centre for Disease Prevention and Control. COVID-19 vaccination and prioritisation strategies in the EU/EEA; Stockholm: ECDC; 2020.
28. Frasca D, Diaz A, Romero M, Mendez NV, Landin AM, Ryan JG, et al. Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. Vaccine 2013;31:3603-10.
[CROSSREF] [PUBMED] [PMC]
29. Li Volti S, Caruso-Nicoletti M, Biazzo F, Sciacca A, Mandara G, Mancuso M, et al. Hyporesponsiveness to intradermal administration of hepatitis B vaccine in insulin dependent diabetes mellitus. Arch Dis Child 1998;78:54-7.
[CROSSREF] [PUBMED] [PMC]
30. Looijmans-Van den Akker I, Verheij TJ, Buskens E, Nichol KL, Rutten GE, Hak E. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care 2006;29:1771-6.
[CROSSREF] [PUBMED]
31. Smith SA, Poland GA. Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care 2000;23:95-108.
[CROSSREF] [PUBMED]
32. American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2021. Diabetes Care 2021;44(Suppl 1):S40-52.
[CROSSREF] [PUBMED] [PDF]
33. Lampasona V, Secchi M, Scavini M, Bazzigaluppi E, Brigatti C, Marzinotto I, et al. Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study. Diabetologia 2020;63:2548-58.
[CROSSREF] [PUBMED] [PMC]
34. Kesavadev J, Misra A, Das AK, Saboo B, Basu D, Thomas N, et al. Suggested use of vaccines in diabetes. Indian J Endocrinol Metab 2012;16:886-93.
[CROSSREF] [PUBMED] [PMC]
35. Ulivieri FM, Banfi G, Camozzi V, Colao A, Formenti AM, Frara S, et al. Vitamin D in the COVID-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel. Endocrine 2021;72:597-603.
[CROSSREF] [PUBMED] [PMC]
36. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020;395:1845-54.
[CROSSREF] [PUBMED] [PMC]
37. Fuggle NR, Singer A, Gill C, Patel A, Medeiros A, Mlotek AS, et al. Correction to: how has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey. Osteoporos Int 2021;32:801.
[CROSSREF] [PUBMED] [PMC]
38. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension. J Bone Miner Res 2018;33:190-8.
[CROSSREF] [PUBMED]
39. Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos Int 2018;29:41-7.
[CROSSREF]
40. Franquemont S, Galvez J. Subacute thyroiditis after mRNA vaccine for COVID-19. J Endocr Soc 2021;5(Suppl 1):A956-7.
[CROSSREF]
41. Iremli BG, Sendur SN, Unluturk U. Three cases of subacute thyroiditis following SARS-CoV-2 vaccine: post-vaccination ASIA syndrome. J Clin Endocrinol Metab 2021;106:2600-5.
[CROSSREF] [PUBMED]
42. Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, Medina G, Sanchez Valadez TI, Jara LJ. Two cases of Graves’ disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid 2021 May 3 [Epub].
https://doi.org/10.1089/thy.2021.0142
.
[CROSSREF]
43. Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 2021;20:102792.
[CROSSREF] [PUBMED] [PMC]
44. Okpechi SC, Fong JT, Gill SS, Harman JC, Nguyen TH, Chukwurah QC, et al. Global sex disparity of COVID-19: a descriptive review of sex hormones and consideration for the potential therapeutic use of hormone replacement therapy in older adults. Aging Dis 2021;12:671-83.
[CROSSREF] [PUBMED] [PMC]
45. Acheampong DO, Barffour IK, Boye A, Aninagyei E, Ocansey S, Morna MT. Male predisposition to severe COVID-19: review of evidence and potential therapeutic prospects. Biomed Pharmacother 2020;131:110748.
[CROSSREF] [PUBMED] [PMC]
46. Klein SL, Dhakal S, Ursin RL, Deshpande S, Sandberg K, Mauvais-Jarvis F. Biological sex impacts COVID-19 outcomes. PLoS Pathog 2020;16:e1008570.
[CROSSREF] [PUBMED] [PMC]
47. Alkhouli M, Nanjundappa A, Annie F, Bates MC, Bhatt DL. Sex differences in case fatality rate of COVID-19: insights from a multinational registry. Mayo Clin Proc 2020;95:1613-20.
[CROSSREF] [PUBMED]
48. Qiao Y, Wang XM, Mannan R, Pitchiaya S, Zhang Y, Wotring JW, et al. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2. Proc Natl Acad Sci U S A 2021;118:e2021450118.
[CROSSREF] [PUBMED]
49. Ciaglia E, Vecchione C, Puca AA. COVID-19 infection and circulating ACE2 levels: protective role in women and children. Front Pediatr 2020;8:206.
[CROSSREF] [PUBMED] [PMC]
50. Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med 2020;8:e20.
[CROSSREF] [PUBMED] [PMC]
51. Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N=4532). Ann Oncol 2020;31:1040-5.
[CROSSREF] [PUBMED]
52. Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA 2021;325:1101-2.
[CROSSREF] [PUBMED] [PMC]
53. Tresoldi AS, Sumilo D, Perrins M, Toulis KA, Prete A, Reddy N, et al. Increased infection risk in Addison’s disease and congenital adrenal hyperplasia. J Clin Endocrinol Metab 2020;105:418-29.
[CROSSREF] [PUBMED]